Type 1 diabetes (T1D) is a relentless autoimmune disease that affects millions of people worldwide, striking children and adults alike. Unlike type 2 diabetes, which is often linked to lifestyle factors, T1D occurs when the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. This leaves patients dependent on lifelong insulin therapy and vulnerable to life-threatening complications such as hypoglycemia, ketoacidosis, and long-term vascular damage. The search for a cure has been the driving force behind organizations like JDRF (formerly the Juvenile Diabetes Research Foundation), which has committed billions of dollars to research. A central pillar of JDRF’s strategy is the development of vaccines and immune tolerance therapies that can stop the autoimmune assault before it destroys the pancreas—offering the hope of prevention, delay, or even reversal of the disease.

Understanding T1D: The Autoimmune Attack

To appreciate the complexity of vaccines and immune tolerance therapies, one must first understand the underlying immunopathology of T1D. The disease is characterized by a breakdown of self-tolerance, leading to the infiltration of autoreactive T cells into the pancreatic islets. These T cells, particularly CD8+ cytotoxic T cells, destroy beta cells. The process is often silent for months or years, detected only by the presence of autoantibodies against insulin, glutamic acid decarboxylase (GAD65), insulinoma-associated antigen-2 (IA-2), or zinc transporter 8 (ZnT8).

JDRF has been instrumental in funding the research that delineated the stages of T1D. Stage 1 is defined by the presence of two or more autoantibodies without symptoms. Stage 2 includes abnormal blood sugar levels (dysglycemia) but no clinical symptoms. Stage 3 is the clinical onset of T1D requiring insulin. This staging framework has allowed researchers to identify high-risk individuals long before they become insulin-dependent, creating a window for intervention. Vaccines and immune tolerance therapies aim to modulate the immune system during Stage 1 or Stage 2, or even earlier in genetically susceptible individuals, to prevent progression to clinical disease.

The Quest for Vaccines: Preventing the Immune Attack

Antigen-Specific Immunotherapy

Traditional vaccines work by exposing the immune system to a harmless form of a pathogen to generate protective memory. In the context of T1D, the goal is reversed: researchers seek to induce immune tolerance to specific beta-cell antigens, essentially teaching the immune system to recognize these self-proteins as harmless and stop the attack. This approach is called antigen-specific immunotherapy (ASI), and JDRF has been a leading funder of clinical trials investigating several candidates.

One of the most studied antigens is GAD65. The drug Diamyd (GAD-alum) was tested in multiple trials, including the large-scale Phase 3 trials funded by JDRF and others. While results have been mixed, meta-analyses suggest a benefit in certain subgroups, particularly individuals with a specific HLA genotype. More recently, JDRF has supported trials of a proinsulin peptide vaccine and an intranasal insulin vaccine designed to induce mucosal tolerance. These studies, many run through the Type 1 Diabetes TrialNet (an international research consortium co-funded by JDRF), have shown modest preservation of C-peptide—a marker of beta-cell function—in some participants.

JDRF has also invested in novel vaccine platforms using modified peptides, liposome-based delivery, and DNA vaccines. For example, a Phase 1 trial of a multi-peptide vaccine (combining several beta-cell antigens) is ongoing with JDRF support at the University of Florida. The hypothesis is that targeting multiple antigens simultaneously may be more effective than single-antigen approaches.

Whole-Cell and Modified Cell Vaccines

Another frontier is the use of engineered immune cells as vaccines. Dendritic cells (DCs) are the sentinels of the immune system, capable of presenting antigens to T cells. JDRF has funded research into tolerogenic dendritic cells (tol-DCs) that are loaded with beta-cell antigens and designed to promote regulatory T cell (Treg) responses rather than effector responses. A Phase 1 trial at the University of Pittsburgh, supported by JDRF, demonstrated safety and proof-of-concept.

Similarly, JDRF has backed the development of Treg cell vaccines. These therapies expand a patient’s own regulatory T cells ex vivo and then reinfuse them to suppress the autoimmune response. JDRF holds equity in several biotech companies, such as Caladrius (which acquired Treg technology) and Sangamo Therapeutics, that are advancing Treg cell therapies. The field is still early, but JDRF’s strategic funding—often through its JDRF T1D Fund—has de-risked these approaches and brought them closer to clinical application.

Immune Tolerance Therapies: Halting Progression

While vaccines aim to prevent the initial immune attack, immune tolerance therapies are designed to stop or reverse an ongoing autoimmune response. These therapies can be broadly classified into monoclonal antibodies, cell-based therapies, and small molecule inhibitors.

Monoclonal Antibodies

The most notable success story in T1D immunotherapy is teplizumab, an anti-CD3 monoclonal antibody. Teplizumab binds to the CD3 complex on T cells, selectively modulating the immune response. In a landmark JDRF-funded study called the At-Risk Trial (also known as the TN10 trial), teplizumab delayed the onset of clinical T1D by an average of two years in relatives at high risk. This led to FDA approval in 2022—the first drug ever licensed to delay T1D. JDRF’s role in the science and advocacy behind teplizumab cannot be overstated: the foundation funded early preclinical work at Columbia University, supported the Phase 2 trials, and helped design the pivotal Phase 3. The drug is now marketed as Tzield by Provention Bio (now part of Sanofi).

Other monoclonal antibodies have also shown promise. Abatacept (CTLA4-Ig) blocks costimulation between T cells and antigen-presenting cells. A JDRF-supported TrialNet study demonstrated that abatacept preserved beta-cell function in newly diagnosed patients. Rituximab (anti-CD20), which depletes B cells, showed a temporary benefit but significant side effects. Alefacept (LFA-3-Ig) preserved C-peptide in some patients but was later withdrawn. JDRF continues to fund studies combining these agents or using them in different disease stages.

Cell-Based Therapies

Cell therapy represents a more sophisticated approach to immune tolerance. JDRF has invested heavily in regulatory T cell (Treg) therapy. Early Phase 1 trials using polyclonal Treg infusions showed safety and trends toward preserved beta-cell function. These studies, conducted at centers such as the University of California, San Francisco and King’s College London, were largely funded by JDRF. Recent advances include antigen-specific Tregs engineered with chimeric antigen receptors (CAR-Tregs) that home to the pancreas. JDRF has funded several academic-industry partnerships to bring CAR-Tregs to clinical testing.

Mesenchymal stem cells (MSCs) have also been investigated for their immunomodulatory properties. JDRF-supported trials of umbilical cord-derived MSCs have shown some success in preserving C-peptide. Tolerogenic dendritic cells, mentioned earlier, are also considered a cell-based therapy approach. JDRF’s research strategy emphasizes the need for robust biomarkers to identify which patients will respond to which cellular therapy.

Kinase Inhibitors and Small Molecules

A rapidly emerging class of therapies is small molecules that target intracellular signaling pathways involved in autoimmunity. JAK inhibitors, which block Janus kinases, have shown remarkable results. In a Phase 2 trial funded by JDRF and published in Nature Medicine, baricitinib (a JAK1/JAK2 inhibitor) preserved beta-cell function in newly diagnosed patients. The drug is already approved for rheumatoid arthritis, which accelerates regulatory pathways. JDRF is now supporting a Phase 3 study of baricitinib for T1D. Similarly, JDRF funded preliminary studies of low-dose IL-2 to boost Tregs, and of antithymocyte globulin (ATG) combined with G-CSF to induce tolerance.

JDRF’s Strategic Investments and Collaborations

Research Networks and Consortia

JDRF does not simply write checks—it builds ecosystems. The foundation is the single largest private funder of T1D research globally, but its impact multiplies through strategic alliances. JDRF co-founded TrialNet, the world’s largest clinical trial network for T1D prevention and early intervention. TrialNet screens tens of thousands of relatives each year and runs numerous immune intervention studies at no cost to participants. JDRF also partners with the Immune Tolerance Network (ITN), an international consortium funded by the NIH, to accelerate biomarker discovery and clinical trials.

The JDRF T1D Fund, a venture philanthropy arm, has invested over $100 million in biotech companies focused on immunotherapies. It has taken equity stakes in companies like Provention Bio (teplizumab), Caladrius (Tregs), and Kyverna (CAR-Tregs). This model allows JDRF to exert influence over company strategy and de-risk unconventional approaches that traditional venture capital might avoid.

Global Partnerships

JDRF collaborates with academic institutions, pharmaceutical companies, and other foundations. The Helmsley Charitable Trust has co-funded several large initiatives, such as the Beta Cell Regeneration Consortium. JDRF has also partnered with the National Institutes of Health (NIH) on the NIDDK’s Type 1 Diabetes Special Statutory Funding Program. These collaborations allow JDRF to leverage additional funding and expertise, ensuring that promising therapies move through the pipeline efficiently.

Recent Breakthroughs and Future Directions

2022 marked a watershed year: the FDA approval of teplizumab (Tzield) to delay T1D. This was the first disease-modifying therapy for T1D and validated the concept of immune intervention. JDRF’s long-term investment had finally paid off in a tangible, approved medicine. But the work is far from over.

Recent trials from JDRF-funded investigators suggest that combination therapies may be more effective than single agents. For instance, a study combining teplizumab with Treg therapy showed enhanced preservation of C-peptide in mouse models, and human trials are being planned. JDRF is also exploring the use of baricitinib in combination with antigen-specific vaccines to induce deeper tolerance.

Another exciting direction is the development of vaccines that can be administered at birth to children at high genetic risk. JDRF is supporting the Global Platforms for the Prevention of Autoimmune Diabetes (GPPAD) initiative, which is testing oral insulin and other interventions in infants. The goal is to prime the immune system before it ever encounters the beta cell in a destructive way.

JDRF’s strategic plan for the next decade focuses on three pillars: prevention (delaying or stopping the disease before clinical onset), reversal (restoring normal blood sugar control after diagnosis), and restoration (regenerating beta cells). Immune tolerance therapies are the linchpin of the prevention and reversal axes. The foundation is also investing in artificial intelligence to predict which therapies will work best for which patient, moving toward precision immunotherapy.

How You Can Support JDRF’s Mission

The progress described above would not be possible without sustained public support. JDRF relies on donations, advocacy, and volunteer engagement to fund research and influence policy. Here are concrete ways to contribute:

  • Donate: Every dollar donated to JDRF goes directly into research or programs. A donation of $50 can fund one hour of laboratory work; $500 can support a screening kit for a family member at risk.
  • Participate in a clinical trial: TrialNet screens relatives of people with T1D free of charge. If you or a loved one are at risk, getting screened can open doors to prevention trials. High-risk individuals may qualify for studies of teplizumab or other experimental vaccines. Visit TrialNet’s website to see if you’re eligible.
  • Advocate: JDRF’s Advocacy team fights for increased federal funding for T1D research (such as the Special Diabetes Program) and for insurance coverage of preventive therapies. Write to your members of Congress or join JDRF’s Advocacy Day.
  • Join a walk or gala: JDRF One Walks, Ride to Cure Diabetes, and local galas raise millions each year. Fundraising not only supports research but also builds community awareness.

No action is too small. The rapid acceleration of immune tolerance therapies—from a laboratory concept to an FDA-approved drug—is a testament to what focused research and community support can achieve. JDRF’s mission is to create a world without T1D, and vaccines and immune tolerance therapies are the most promising path to that future. With continued investment and participation, the next decade could bring even more breakthroughs, preventing T1D in thousands of children and adults each year and offering hope for a cure. Your involvement makes that possible.